Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 55Ovarian Neoplasms 39Carcinoma, Hepatocellular 39Neoplasms 25Fallopian Tube Neoplasms 21Carcinoma, Non-Small-Cell Lung 20Endometrial Neoplasms 14Glioblastoma 11Breast Neoplasms 11Brain Neoplasms 11Colonic Neoplasms 10Neoplasm Metastasis 9Lung Neoplasms 8Liver Neoplasms 8Uterine Cervical Neoplasms 7Stomach Neoplasms 6Rectal Neoplasms 6Glioma 6Biliary Tract Neoplasms 6Carcinoma, Ovarian Epithelial 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Small Cell Lung Carcinoma 3Sarcoma 3Recurrence 3Peritoneal Neoplasms 3Pancreatic Neoplasms 3Neoplasms, Nerve Tissue 3Gastrointestinal Neoplasms 3

Interventions

relatlimab 1pembrolizumab 1fludarabine phosphate 1fludarabine 1Nivolumab 1Cyclophosphamide 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Microsatellite Instability × Bevacizumab × 90 days × Clear all
NCT06004245 2026-05-08

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

Vividion Therapeutics, Inc.

Phase 1 Recruiting
280 enrolled
Gastrointestinal

Colorectal Neoplasms, Microsatellite Instability

Data powered by HemOnc (CC BY 4.0) Colophon âš¡